Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board - Seite 2
Ryan Vandrey, Ph.D., The Johns Hopkins University School of Medicine
Ryan Vandrey, Ph.D., is a professor of Psychiatry and Behavioral Sciences. Dr. Vandrey's research focuses primarily on the behavioral pharmacology of cannabis (marijuana) and includes controlled laboratory studies with adult research volunteers, clinical trials, web-based survey research, and natural history studies with patient populations using cannabis/cannabinoids for therapeutic purposes.
Alison O’Mahony, Ph.D., Eurofins Discovery
Alison O’Mahony, Ph.D., is the Vice President of Translational Biology in the Phenotypic Services Unit of Eurofins Discovery. She has extensive expertise in translational biology in the areas of autoimmunity, inflammation, fibrosis, immuno-oncology (I-O), cardiovascular, skin, pulmonary diseases and oncology.
Anupama Kumar, M.B.B.S., The Johns Hopkins University School of Medicine
Anupama Kumar, M.B.B.S., is a Research Associate, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine. Anupama is also the Co-Director of Johns Hopkins TREAT Depression Clinic and is skilled in planning and running Phase II and III clinical trials.
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity. SUPERA-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. SUPERA-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.